You searched for: c1-esterase inhibitors

16970 results

F06. Specialised Immunology and Allergy Services

Scope This Clinical Reference Group (CRG) covers specialised treatment of certain immunological and allergic conditions. In relation to immunological conditions, this includes primary immunodeficiencies, autoimmune and autoinflammatory disease where there is associated immunodeficiency, complex autoimmune and vasculitic conditions and autoinflammatory syndromes. In relation to allergic conditions this includes severe, complex and/or rare sub-groups. Membership Dr. […]

Policies: Routinely commissioned

A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide. Abatacept for […]

Clinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages)

This policy document outlines the arrangements for funding of treatment for people with congenital haemophilia A with factor VIII inhibitors.

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults)

Contents Commissioning position Evidence and policy summary Implementation Eligibility criteria Exclusion criteria and cautions Pregnancy and women of childbearing potential Dose Co-administration Safety reporting Marketing authorisation Governance Off-label use of medication Data collection requirement Clinical outcome review Policy review date Equality statement Definitions References Rapid Policy Statement Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or […]

Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults)

Contents Commissioning position Evidence and policy summary Implementation Governance Equality statement Definitions References   Publications approval reference: C1600 Rapid Policy Statement 31 January 2022 Commissioning position The proposal is: Tocilizumab is recommended to be available as a treatment option through routine commissioning for adult patients (aged 18 years and older) hospitalised with COVID- 19 in […]

Prescribed Services CQUIN Scheme: BI1 Improving Hepatitis C Virus treatment pathways through Operational Delivery Networks

This document contains information on the Prescribed Services Commissioning for Quality and Innovation (CQUIN) scheme 2017-19: BI1 Improving Hepatitis C Virus treatment pathways through Operational Delivery Networks.